Phase 3 Pneumococcal Vaccine Study for Children and Adolescents at High-Risk (STRIDE-13)

Purpose

STRIDE-13 is a pneumococcal vaccine research trial for children and adolescents with chronic disease (or chronic medical conditions). The purpose of the STRIDE-13 trial is to test an investigational trial vaccine that may help protect against pneumococcal disease.

About Pneumococcal Disease

Pneumococcal disease is an illness caused by certain germs (bacteria) called Streptococcus pneumoniae. These germs can cause serious infections in the ears, nose, lungs, blood, or brain. These infections can occur more frequently or be worse in children with chronic disease.

Is my child eligible?

Your child may qualify to take part in this trial if they are aged 2 to 17 years old and:

• Is being treated for one of these conditions:
  • Diabetes
  • Chronic liver disease
  • Chronic lung disease
  • Chronic heart disease
  • Chronic kidney disease
• Has completed the recommended childhood pneumococcal conjugate vaccine regimen prior to 2 years of age

Other detailed eligibility will be confirmed by study staff.

What does participation involve?

• The study lasts six months
• There are two in-person visits on Day 1 and Day 30, and 3 phone calls (Day 7, Day 90, Day 180)
• Participants are asked to complete daily self-reports of symptoms for the first five days, and then report any adverse effects (side effects) for the first 30 days

The trial vaccine and trial-related tests will be provided at no cost. You may be reimbursed for your trial-related travel expenses.

—

Contact

Name: Karen Caballero

Email: karen.caballero@iwk.nshealth.ca

Phone: (902) 470-8141